Den Europæiske Union - dansk - EMA (European Medicines Agency)

photonamic gmbh & co. kg - 5-aminolevulinsyrehydrochlorid - gliom - antineoplastiske midler - gliolan er indiceret hos voksne patienter til visualisering af malignt væv under operationen for malignt gliom (verdenssundhedsorganisation iii og iv).

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

photonamic gmbh & co. kg - 5-aminolevulinsyre - medicinsk plaster - 8 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

medice arzneimittel pütter gmbh & co. kg - methylphenidathydrochlorid - kapsler med modificeret udløsning, hårde - 10 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

medice arzneimittel pütter gmbh & co. kg - methylphenidathydrochlorid - kapsler med modificeret udløsning, hårde - 20 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

medice arzneimittel pütter gmbh & co. kg - methylphenidathydrochlorid - kapsler med modificeret udløsning, hårde - 30 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

medice arzneimittel pütter gmbh & co. kg - methylphenidathydrochlorid - kapsler med modificeret udløsning, hårde - 40 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

medice arzneimittel pütter gmbh & co. kg - methylphenidathydrochlorid - kapsler med modificeret udløsning, hårde - 50 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

medice arzneimittel pütter gmbh & co. kg - methylphenidathydrochlorid - kapsler med modificeret udløsning, hårde - 60 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosuppressiva - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leukæmi, lymfocytisk, kronisk, b-celle - antineoplastiske midler - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.